Supplementary material

Supplementary Table S1: Radiologic criteria for response assessment

	RECIST 1.1	EASL	mRECIST
COMPLETE	Disappearance of all target	s Disappearance of any	Disappearance of any
RESPONSE	lesions (up to two	intratumoral arterial	intratumoral arterial
(CR)	measurable liver lesions).	enhancement in all	enhancement in all
		measurable arterially-	target lesions (up to two
		enhancing liver lesions.	measurable liver
			lesions).
PARTIAL	At least a 30% decrease in	At least a 50% decrease in	At least a 30% decrease
RESPONSE	the sum of the greatest	the sum of the product of	in the sum of
(PR)	unidimensional diameters	bidimensional diameters of	unidimensional
	of target lesions, taking as	viable (enhancement in the	diameters of viable
	reference the baseline sum	arterial phase) target	(enhancement in the
	of the diameters of target	lesions, taking as reference	arterial phase) target
	lesions.	the baseline sum of the	lesions, taking as
		diameters of the targets	reference the baseline
		lesions.	sum of the diameters of
			the targets lesions.
STABLE DISEASE	Any cases that do not	Any cases that do not	Any cases that do not
(SD)	qualify for either partial	qualify for either partial	qualify for either partial
	response or progressive	response or progressive	response or progressive
	disease	disease.	disease.

PROGRESSIVE

DISEASE (PD)

An increase of at least 20% An increase of at least 25% An increase of at least in the sum of the diameters in the sum of the diameters 20% in the sum of the of target lesions, taking as of the viable target lesions, diameters of the viable reference the smallest sum taking as reference the (enhancing) target of the diameters of target smallest sum of the lesions, taking as lesions recorded since diameters of viable target reference the smallest lesions recorded since sum of the diameters of treatment started. viable target lesions treatment started. recorded since treatment started.